What a innocent Keyman, dare to shout here and mislead ppl. Malaysia covid number coming down is due to laboratory delay in running the COVID-19 test during Chinese New Year festival! We are very sure that some doctors in MOH/ private did not run the COVID-19 test for those asymptomatic probable Covid-19 individuals! 3000+ cases are just the tip of iceberg! When the country is runner by the crooks, the RAKYAT hv to face the musics!
Ordinary investors look at COVID-19 numbers, Smart investors see beyond the numbers! This really illustrates 1% wining rate in stock market!
"That's why not like iddiot karma @apple168 keep on talking non sense negative info but at the same time keep on begging other people selling to this iddiot karma @apple168...
Keyman188 really pity all newbies listen to this non sense iddiot karma @apple168 at the end got nothing ...."
The World Health Organization (WHO) today listed two versions of the AstraZeneca/Oxford COVID-19 vaccine for emergency use, giving the green light for these vaccines to be rolled out globally through COVAX. The vaccines are produced by AstraZeneca-SKBio (Republic of Korea) and the Serum Institute of India.
WHO’s Emergency Use Listing (EUL) assesses the quality, safety and efficacy of COVID-19 vaccines and is a prerequisite for COVAX Facility vaccine supply. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.
“Countries with no access to vaccines to date will finally be able to start vaccinating their health workers and populations at risk, contributing to the COVAX Facility’s goal of equitable vaccine distribution,” said Dr Mariângela Simão, WHO Assistant-Director General for Access to Medicines and Health Products.
‘But we must keep up the pressure to meet the needs of priority populations everywhere and facilitate global access. To do that, we need two things – a scale-up of manufacturing capacity, and developers’ early submission of their vaccines for WHO review.”
The WHO EUL process can be carried out quickly when vaccine developers submit the full data required by WHO in a timely manner. Once those data are submitted, WHO can rapidly assemble its evaluation team and regulators from around the world to assess the information and, when necessary, carry out inspections of manufacturing sites.
In the case of the two AstraZeneca/Oxford vaccines, WHO assessed the quality, safety and efficacy data, risk management plans and programmatic suitability, such as cold chain requirements. The process took under four weeks.
The vaccine was reviewed on 8 February by WHO’s Strategic Advisory Group of Experts on Immunization (SAGE), which makes recommendations for vaccines’ use in populations (i.e. recommended age groups, intervals between shots, advice for specific groups such as pregnant and lactating women). The SAGE recommended the vaccine for all age groups 18 and above.
The AstraZeneca/Oxford product is a viral vectored vaccine called ChAdOx1-S [recombinant]. It is being produced at several manufacturing sites, as well as in the Republic of Korea and India. ChAdOx1-S has been found to have 63.09% efficacy and is suitable for low- and middle-income countries due to easy storage requirements.
Malaysia to get first batch of Pfizer-BioNTech Covid-19 vaccines on Feb 21
(February 16, 2021 09:51 am +08)
KUALA LUMPUR (Feb 16): Malaysia will get its first batch of Covid-19 vaccines produced by US and German drugmakers Pfizer and BioNTech on Feb 21, and kick off its inoculation drive five days after that, Prime Minister Tan Sri Muhyiddin Yassin said on Tuesday.
Muhyiddin said he will be the first to receive a dose of the vaccine when the campaign starts on Feb 26.
"This comprehensive programme is aimed at ensuring herd immunity in the community so that we can stop the spread of Covid-19 infections and bring an end to the pandemic," Muhyiddin said at the launch of the vaccination programme handbook.
Advertisement
Malaysia has seen a sharp spike in coronavirus infections in recent weeks, after having largely reined in the epidemic for most of 2020. It has reported a total of over 260,000 Covid-19 cases, the third highest in Southeast Asia after Indonesia and the Philippines, and 975 deaths.
The Southeast Asian country has said it aims to cover at least 80% of its 32 million population within a year and has secured more than enough vaccines to reach the target.
Apart from its deal with Pfizer and BioNTech, Malaysia also has supply agreements with Britain's AstraZeneca, Russia's Gamaleya Research Institute, and China's Sinovac Biotech Ltd and CanSino Biologics.
Muhyiddin said earlier this month that the first phase of the vaccine rollout from February to April will involve 500,000 frontline workers, followed by 9.4 million high-risk individuals who will be vaccinated between April and August.
A third and final phase will involve more than 16 million adults aged 18 and older, and will run from May to February next year.
The government has said it will extend its free Covid-19 vaccination programme to all foreigners residing in the country, but that priority will be given to Malaysians.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
manegto
684 posts
Posted by manegto > 2021-02-03 10:36 | Report Abuse
DO NOT BUY AIRPORT STOCK.....COMPANY BLEEING MONEY AND GOMEN WILL NOT HELP THEM AS GOMEN OSO BANCRUPT ....